Abstract #301281

This is the preliminary program for the 2003 Joint Statistical Meetings in San Francisco, California. Currently included in this program is the "technical" program, schedule of invited, topic contributed, regular contributed and poster sessions; Continuing Education courses (August 2-5, 2003); and Committee and Business Meetings. This on-line program will be updated frequently to reflect the most current revisions.

To View the Program:
You may choose to view all activities of the program or just parts of it at any one time. All activities are arranged by date and time.

The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.

Back to main JSM 2003 Program page
JSM 2003 Abstract #301281
Activity Number: 213
Type: Contributed
Date/Time: Tuesday, August 5, 2003 : 8:30 AM to 10:20 AM
Sponsor: Section on Statistics in Epidemiology
Abstract - #301281
Title: Impact of Propensity Scores on Estimating Cost Effectiveness of Cancer Treatments
Author(s): Nandita Mitra*+ and Alka Indurkhya
Companies: Memorial Sloan-Kettering Cancer Center and Harvard School of Public Health
Address: Dept. of Epidermiology Biostatistics, New York, NY, 10021,
Keywords: propensity scores ; cost effectiveness ; nonignorable treatment assignment ; SEER-Medicare
Abstract:

The cost-effectiveness ratio (CER), defined as the ratio of the difference in cost of an experimental versus standard treatment to the difference in effectiveness of the therapies, is a popular statistic that is used by policy and decision makers. Recently, the net monetary benefit (NMB) has been proposed as an alternative statistical summary measure to overcome the limitations associated with the CER. Propensity scores are used to balance any significant differences in baseline measures and demographic characteristics between the treatment groups. We conduct Monte-carlo simulation studies to better understand the role of propensity scores in (a) obtaining adjusted costs and benefits of treatment protocols and (b) estimating the CER and NMB. We assess the sensitivity of propensity score adjusted cost-effectiveness measures to non-ignorable treatment assigment via a regression model based approach. SEER-Medicare data for the treatment of Stage II/III bladder cancer are used to demonstrate these methods.

  • The address information is for the authors that have a + after their name.
  • Authors who are presenting talks have a * after their name.

Back to the full JSM 2003 program

JSM 2003 For information, contact meetings@amstat.org or phone (703) 684-1221. If you have questions about the Continuing Education program, please contact the Education Department.
Revised March 2003